Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Mark Awad, Ph.D., M.D.

Co-Author

This page shows the publications co-authored by Mark Awad and Patrick Ott.
Connection Strength

0.474
  1. A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. Cell. 2020 10 15; 183(2):347-362.e24.
    View in: PubMed
    Score: 0.231
  2. Safety of Immune Checkpoint Inhibitors in Patients With Pre-Existing Inflammatory Bowel Disease and Microscopic Colitis. JCO Oncol Pract. 2020 09; 16(9):e933-e942.
    View in: PubMed
    Score: 0.056
  3. Palliative Radiation Therapy for Vertebral Metastases and Metastatic Cord Compression in Patients Treated With Anti-PD-1 Therapy. Front Oncol. 2019; 9:199.
    View in: PubMed
    Score: 0.052
  4. Radiation and PD-1 inhibition: Favorable outcomes after brain-directed radiation. Radiother Oncol. 2017 07; 124(1):98-103.
    View in: PubMed
    Score: 0.046
  5. Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. Cancer Immunol Res. 2017 04; 5(4):312-318.
    View in: PubMed
    Score: 0.045
  6. PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course. Clin Cancer Res. 2016 Dec 15; 22(24):6051-6060.
    View in: PubMed
    Score: 0.043
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.